Elicio Therapeutics, Inc ( (ELTX) ) has released its Q3 earnings. Here is a breakdown of the information Elicio Therapeutics, Inc presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer patients with limited treatment options. In its latest earnings report, Elicio Therapeutics highlighted its ongoing efforts in advancing its product candidates, despite facing financial challenges. The company reported a net loss of $31.9 million for the nine months ended September 30, 2025, compared to a net loss of $37.9 million in the same period of 2024. The company’s cash and cash equivalents increased to $20.6 million as of September 30, 2025, up from $17.6 million at the end of 2024, primarily due to financing activities including a public offering and an at-the-market equity program. Elicio Therapeutics continues to focus on the development of its lead product candidate, ELI-002 7P, and other pipeline products, while seeking additional funding to support its operations. Looking ahead, the company plans to address its financial needs through various capital sources, including potential partnerships and collaborations, as it continues to pursue its strategic objectives in the biotechnology sector.